Brochure Mechanical Seal Technology and Selection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Photoaging & Skin Damage
Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg. -
Glycolic Acid
Glycolic Acid Pharmacy Compounding Advisory Committee Meeting November 3, 2016 Jane Liedtka, MD Clinical Reviewer Division of Dermatology and Dental Products, Office of Drug Evaluation III Glycolic Acid Review Team Jane Liedtka, MD, Clinical Reviewer, DDDP, ODE3 Ben Zhang, PhD, Chemistry Reviewer, OPQ Jianyong Wang, PhD, Pharmacology/Toxicology Reviewer, DDDP, ODE3 Doanh Tran, PhD., Clinical Pharmacology Team Leader, DCP3, OCP www.fda.gov 2 Nomination • Glycolic acid, 0.08% to 70%, has been nominated for inclusion on the list of bulk drug substances for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for topical use in the treatment of hyperpigmentation disorders and photodamaged skin www.fda.gov 3 Background • Glycolic acid is currently available in cosmetic formulations (creams, pads, and lotions) and present as excipient in some topical drug products www.fda.gov 4 Regulatory Definitions: Drugs and Cosmetics • Whether a product is a cosmetic or a drug under the law is determined by a product's intended use; different laws and regulations apply to each type of product • A drug is an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or an article (other than food) that is intended to affect the structure or function of the body • A cosmetic is an article (other than soap) intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance – Regulated by CFSAN – No premarket approval of products or ingredients (except color additives) www.fda.gov 5 Cosmetic and Drug Uses of Topical Acids • Topical Acids cause exfoliation, or shedding of the skin surface. -
Acne Treatment: Easy Ways Hospital Family Medicine Residency Program, French Camp, Calif to Improve Your Care [email protected]
CASE c Tam T. Nguyen, MD San Joaquin General Acne treatment: Easy ways Hospital Family Medicine Residency Program, French Camp, Calif to improve your care [email protected] The author reported no For patients of any age, facial lesions can cause potential conflict of interest relevant to this article. considerable embarrassment and distress. Read on to discover what key component of acne treatment you should be using (but probably aren’t) and which dosage you can safely lower. c Practice CASE Janis S, an otherwise healthy 19-year-old, is in your recommendations office, seeking treatment for acne. She reports she has tried various over-the-counter (oTc) creams in recent months, but › Use a classification system, has seen little improvement. The acne first appeared about such as that of the American 5 years ago, and her pediatrician prescribed topical adapalene Academy of Dermatol- and doxycycline. The treatment helped, but she says her face ogy, to assess the severity never fully cleared up; over the past year, the acne has gotten of acne vulgaris. A worse. › Treat inflamma- on examination, you find several nodules and comedones tory lesions aggressively on the patient’s face, chest, and back. ms. S confides in you to prevent scarring. A that the acne—particularly on her face—kept her from going › When isotretinoin is to the senior prom. indicated, consider prescrib- ing a lower dosage (but ore than 80% of adolescents and adults develop longer duration) than the acne vulgaris at some point in their lives, and in traditional regimen. B at least 15% to 20% of cases, the acne is moderate M1 Strength of recommendation (SOR) to severe. -
PDO Thread Lift and Smoothing
PDO Thread Li and Smoothing Pre-Care and Post-Care Instrucons Pre-Care Instrucons 2 WEEKS BEFORE: ● Avoid taking (unless medically necessary) aspirin, non-steroidal an-inflammatory medicaons such as ibuprofen, Aleve, Advil, Motrin or supplements such as St. John’s Wort, Vitamin E, Fish oil/Omega 3/Flax Seed oil or Melatonin. These agents may increase bruising and bleeding risk. Tylenol is acceptable. Please let Renew Med Spa know if you are on any medicaon, such as blood thinners, that may increase your risk of bruising and/or bleeding. 1 WEEK BEFORE: ● Avoid any topical skincare products that may irritate your skin such as glycolic acid, salicylic acid or renoic (renols) acids. ● If you have any recent skin injecon, acve acne or cold sore in the treatment area, please call our office immediately to reschedule your appointment. 1 DAY BEFORE: ● Oral Arnica should be taken to minimize risk of swelling and bruising. Take Arnica the day before your treatment. ● Please nofy Renew Med Spa or our staff if you have a history of more than 3 facial cold sores a year, as there is a risk that this procedure could cause a recurrence. You can take Valtrex, 2 grams the night before your procedure and another 2 grams 12 hours aer the procedure to prevent cold sores recurrence. DAY OF PROCEDURE: ● Local numbing medicaon will be used to maximize your comfort during the procedure. Most paents report a mild to moderate snging sensaon with numbing injecons. It is important to discuss any sensivity or allergy to Lidocaine, Novocaine or Epinephrine with your provider prior to treatment. -
Inside This Issue
Volume 5 | Issue 1 | SkinCare Physicians | 2008 Edition 1244 Boylston Street, Chestnut Hill, MA 02467 | Phone: (617) 731-1600 | Fax: (617) 731-1601 SKINCARE PRESCRIPTION ARRIVES ! After years of exhaustive research and development, on the market, it can be confusing. To simplify SkinCare Physicians is proud to introduce our the skin care process, we have chosen the most new proprietary line of products, SKINCARE innovative and important ingredients available to PRESCRIPTION. With over 100 years of combined create a line of 8 products that our patients can use experience and expertise in skin care, the daily to care for their skin. dermatologists at SkinCare Physicians are uniquely positioned to develop this innovative product line. Unlike all the other products out there, SKINCARE The 8 products include: PRESCRIPTION is different. • Cleanser • Exfoliator The concept behind SKINCARE PRESCRIPTION is • Day Anti-Aging Moisturizer AHA with SPF 15 simple: provide a small group of carefully chosen • Night Anti-Aging Moisturizer with Retinol products that actually improve your skin, and at a • Anti-Aging Eye Cream reasonable price. Most patients use many different • Intensive Anti-Wrinkle Moisturizer (with the products, are never sure just which ones to use SkinCare Physicians special formula) when, and pay too much for them. Every day patients • Age Prevention Vitamin C Serum ask us about the products they should use to keep • Age Reversal Glycolic Acid Serum 10% their skin healthy and young looking, and because there are so many different products to choose from ( continued on page 2 ) YOUTH IN A SYRINGE: THE NEW WAY TO GET DRAMATIC RESULTS WITH FILLERS AND BOTOX INSIDE THIS ISSUE: While it may sound too good to be true, it has never lines between the eyes by combining Restylane been easier to achieve extraordinary results that can or Juvederm with Botox, creating improvement make you look younger in minutes. -
APPENDIX G Acid Dissociation Constants
harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants § ϭ 0.1 M 0 ؍ (Ionic strength ( † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form. -
WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/227293 Al 20 December 2018 (20.12.2018) W ! P O PCT (51) International Patent Classification: c/o Jack Bell Research Centre, 2660 Oak Street, Vancouver, A61K 47/30 (2006.01) C08G 63/08 (2006.01) British Columbia V6H 3Z6 (CA). A61K 47/10 (2017.01) C08G 65/28 (2006.01) (74) Agent: MACINS, Andris; Unit 203A - 116 Geary Avenue, A61K 47/34 (2017.01) Toronto, Ontario M6H 4H1 (CA). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CA20 18/0507 14 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 13 June 2018 (13.06.2018) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/5 18,800 13 June 2017 (13.06.2017) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: THE UNIVERSITY OF BRITISH COLUM¬ TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Harmonized Tariff Schedule of the United States (2020) Revision 14 Annotated for Statistical Reporting Purposes
Harmonized Tariff Schedule of the United States (2020) Revision 14 Annotated for Statistical Reporting Purposes SECTION VI PRODUCTS OF THE CHEMICAL OR ALLIED INDUSTRIES VI-1 Notes 1. (a) Goods (other than radioactive ores) answering to a description in heading 2844 or 2845 are to be classified in those headings and in no other heading of the tariff schedule. (b) Subject to paragraph (a) above, goods answering to a description in heading 2843, 2846 or 2852 are to be classified in those headings and in no other heading of this section. 2. Subject to note 1 above, goods classifiable in heading 3004, 3005, 3006, 3212, 3303, 3304, 3305, 3306, 3307, 3506, 3707 or 3808 by reason of being put up in measured doses or for retail sale are to be classified in those headings and in no other heading of the tariff schedule. 3. Goods put up in sets consisting of two or more separate constituents, some or all of which fall in this section and are intended to be mixed together to obtain a product of section VI or VII, are to be classified in the heading appropriate to that product, provided that the constituents are: (a) Having regard to the manner in which they are put up, clearly identifiable as being intended to be used together without first being repacked; (b) Entered together; and (c) Identifiable, whether by their nature or by the relative proportions in which they are present, as being complementary one to another. Additional U.S. Notes 1. In determining the amount of duty applicable to a solution of a single compound in water subject to duty in this section at a specific rate, an allowance in weight or volume, as the case may be, shall be made for the water in excess of any water of crystallization which may be present in the undissolved compound. -
Felix Ekness
ABSTRACT A Synthetic Biology Approach to Engineering Bacterial Two- Component Systems for Sensor Development and Discovery of Anti-Virulence Agents by Felix Ekness Bacterial two-component systems (TCSs) are the largest family of signal transduction pathways that enable bacteria to sense a diversity of stimuli including small peptides, environmental pollutants, and light. Canonical TCSs are composed of a transmembrane sensor histidine kinase (SK) that converts stimulus detection into phosphorylation of a cognate response regulator (RR). Upon phosphorylation, the cytoplasmic RR binds target output promoters, hereby modulating gene expression. TCSs are valuable sensors for synthetic biology due to their diverse sensing capabilities and straightforward transduction of detected stimulus into transcriptional regulation. TCSs are also emerging targets for novel therapeutic development due to their extensive role in regulating bacterial virulence and antibiotic resistance. Although TCSs are exciting sensors for synthetic biology and targets for therapeutic applications, most TCSs remain difficult to harness for applications and study due to output promoters that are unknown, subject to cross- regulation, or silent in heterologous hosts. In the first portion of my work, I develop a method to overcome the hurdles in characterizing and utilizing TCSs as biosensors. Through the framework of synthetic biology, I demonstrate that the two largest families of RR DNA binding domains (DBDs) can be interchanged with remarkable flexibility, enabling the corresponding TCSs to be rewired to synthetic output promoters. In collaboration with Kristina Daeffler, we exploit this plasticity to eliminate cross-regulation and in collaboration with Brian Landry, we un-silence a gram-negative TCS in a gram-positive host and engineer a sensor with over 1,300-fold activation. -
Accepted Manuscript
Accepted Manuscript Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site Min Zhao, Esther Rodríguez Villagra, Laura Kowalczuk, Manon Le Normand, Marianne Berdugo, Rinath Levy-Boukris, Ikram El Zaoui, Béatrice Kaufmann, Robert Gurny, Irene Bravo-Osuna, Irene T. Molina-Martínez, Rocío Herrero-Vanrell, Francine Behar-Cohen PII: S0168-3659(17)30862-3 DOI: doi:10.1016/j.jconrel.2017.09.029 Reference: COREL 8972 To appear in: Journal of Controlled Release Received date: 14 June 2017 Revised date: 20 September 2017 Accepted date: 21 September 2017 Please cite this article as: Min Zhao, Esther Rodríguez Villagra, Laura Kowalczuk, Manon Le Normand, Marianne Berdugo, Rinath Levy-Boukris, Ikram El Zaoui, Béatrice Kaufmann, Robert Gurny, Irene Bravo-Osuna, Irene T. Molina-Martínez, Rocío Herrero- Vanrell, Francine Behar-Cohen , Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:10.1016/j.jconrel.2017.09.029 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT TOLERANCE OF HIGH AND LOW AMOUNTS OF PLGA MICROSPHERES LOADED WITH MINERALOCORTICOID RECEPTOR ANTAGONIST IN RETINAL TARGET SITE Min Zhao1,2,3*, Esther Rodríguez Villagra4,5*, Laura Kowalczuk6, Manon Le Normand1,2,3, Marianne Berdugo1,2,3, Rinath Levy-Boukris1,2,3, Ikram El Zaoui1,2,3, Béatrice Kaufmann7, Robert Gurny7, Irene Bravo-Osuna4,5, Irene T. -
United States Patent Office Patented Mar
3,238,221 United States Patent Office Patented Mar. 1, 1966 1. 2 3,238,221 Aryl Sulfonamides suitable for the production of the TETRAAZAPORPHINE DYESTUFFS dyestuffs of Formula I are, for example, the following: Peter Schnitz, Cologne-Stammheim, and Detlef Delfs, NE Opiaden, Germany, assignors to Farbenfabriken Bayer Aktiengeseischaft, Leverkusen, Germany, a corporation 5 of Germany No Drawing. Filed June 5, 1961, Ser. No. 114,619 (D-on Claims priority, application Germany, June 11, 1960, NH F 31,440 3 Claims. (CI. 260-314.5) 10 : {D-onen The invention relates to new tetraazaporphine dye NH stuffs; more particularly it relates to tetrazaporphine dye stuffs of the general formula / 15 {D-onotor NE A x-N-AR -) (I) In this general formula A represents the residue of a tetraazaporphine dyestuff, in particular of a phthalo (D-Ionicator cyanine dyestuff which may be free of metal or which 20 NE may contain metal atoms, X stands for -CH2-, -SO or -CO-, R means hydrogen, a lower alkyl or hydroxy Substituted lower alkyl radical, Ar represents a residue of the benzene, diphenyl, diphenylamine, diphenyloxide NE 25 CHs or naphthalene series and Y stands for an optionally sub / stituted Sulfonamido or sulfonylamino group, in stands SONEICHN for an integer from 1 to 8. A particularly valuable class of dyestuffs among the Yo Hs compounds of the Formula I are those in which the NH Sulfonamido group Y corresponds to the general formula 30 -SO-NEI-R1-OSO32. (II) {D-onent or -so-N-R-R-R-oso.2 (III) NEI. R2 35 wherein R means an alkylene bridge having 2 or 3 car {Donounction bon atoms between -NH- and -OSOZ, Z is hydro CH3 gen or an alkali metal cation, R2 is a lower alkyl group, N CH4OH Rs represents an alkylene group having 2 to 3 carbon 40 / atoms between SO2NEICHN N CEO NH, and -R4 RA stands for -O-, -S- or 45 { X-so-HN-O In these aniline sulfonamides the sulfonamide group may R6 being hydrogen, R5-OSOZ or a lower alkyl group Stand in o- and preferably in the m- or p-position to the and R5 is a lower alkylene group having 2 to 3 carbon amino group. -
Mechanical Seals Conventional and Gas-Lubricated for Pumps, Compressors, Agitators and Similar Applications
® Mechanical Seals Conventional and Gas-lubricated for Pumps, Compressors, Agitators and Similar Applications. Seal Supply Systems and Components. Design Manual 15.3 BURGMANNinyourvicinity ServiceCenterOst KE-BurgmannU.K. INDIA MYANMAR TAIWAN Germany AirparkMerseburg EatonBank,Congleton OutsideEurope BurgmannIndiaPVT.LTD. OneCo.Ltd. FriendlyTradingCo.,Inc. Hans-Grade-Straße4 GB-CheshireSW121NZ A.K.IndustrialEstate No.22,7Mile,PyayRd., 11Fl.-1,No.1PaoSenRoad Kundenbetreuungs-Center D-06217Merseburg Phone+44/1260/291289 ARGENTINA MadinaManzilCompound MayangoneTownship YongHoCity,TaipeiHsien Nord/WerksbüroBremen Phone+49/3461/842920 Telefax+44/1260/291303 ChilicoteS.A. S.V.Road,Goregaon(West) Yangon,Myanmar Taiwan/R.O.C. SinstorferKirchweg74- 92 Telefax+49/3461/842930 Avda.JulioA.Roca546 Bombay400062 Phone+951244969 Phone+886/22/9279070 D-21 077Hamburg GREECE Phone+91/22/8741534 Telefax+951650469 Telefax+886/22/9279377 ServiceCenterRhein-Main C1067ABNBuenosAires,Argentina Phone+49/421/562375 A.G.Stambolidis&Co. Telefax+91/22/8748810 ImWinkel4 Phone+54/11/43438469 NEWZEALAND THAILAND Telefax+49/421/563396 Mitrodorou22 Telefax+54/11/43314278 BranchOffices:Bangalore,Baroda, D-67547Worms GR-10441Athen Chennay,Cochin,Delhi,Hyderabad, BurgmannSealsNewZealand BurgmannThailandCo.Ltd. Kundenbetreuungs-Center Phone+49/6241/932520 Phone+30/21/05150665 AUSTRALIA Kota,Panvel,Pune,Visakhapatnam, UnitF14ClemwayPlace BangaTowerC,Floor18th Ost/WerksbüroCottbus Telefax+49/6241/932531 Telefax+30/21/05150810 BurgmannSeals Mumbai,Surat. Henderson,Auckland 40/14Moo12Banga-TradRd.